Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling

Oncogene volume 24, pages 4883–4893 (2005)Cite this article

Abstract

We previously reported that 17-β-estradiol (E2)-induced mitochondrial reactive oxygen species (mtROS) act as signaling molecules. The purpose of this study was to investigate the effects of E2-induced mtROS on cell cycle progression. E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimic ebselen. Flow cytometry showed that mitochondrial blockers of protein synthesis (chloramphenicol), transcription and replication (ethidium bromide), and function (rotenone, rhodamine 6G) blocked E2-induced G1 to S transition. Reduction of E2-induced DNA synthesis in the presence of mitochondrial blockers occurred without influencing the level of ATP. Additionally, the mitochondrial blockers inhibited the E2-induced expression of early cell cycle genes such as cyclins D1, D3, E1, E2, and B2. NAC or rotenone reduced E2-induced cyclin D1 expression. Furthermore, E2-induced binding of AP-1 and CREB to the TRE and CRE response sequences, respectively, in the promoter of cyclin D1 was inhibited by NAC or rotenone. In addition, E2-induced expression of PCNA, PRC1, and bcl-2 were inhibited by mitochondrial blockers. These data indicate that E2-induced mtROS are involved in the regulation of early G1-phase progression. Since neither antioxidants nor mitochondrial blockers used in this study are reported to bind the estrogen receptor (ER), our findings suggest that E2-induced mtROS modulates G1 to S transition and some of the early G1 genes through a nongenomic, ER-independent signaling pathway. Thus, our results suggest (1) a new paradigm that estrogen-induced mitochondrial oxidants control the early stage of cell cycle progression and (2) provide the basis for the discovery of novel antioxidant-based drugs or antioxidant gene therapies for the prevention and treatment of estrogen-dependent breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Arteaga E, Villaseca P, Bianchi M, Rojas A and Marshall G . (2003). Menopause, 10, 142–146.

  • Bocchinfuso WP, Hively WP, Couse JF, Varmus HE and Korach KS . (1999). Cancer Res., 59, 1869–1876.

  • Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC and Roninson IB . (2000). Oncogene, 19, 2165–2170.

  • Chen JQ, Delannoy M, Cooke C and Yager JD . (2004a). Am. J. Physiol. Endocrinol. Metab., 286, E1011–E1022.

  • Chen JQ, Eshete M, Alworth WL and Yager JD . (2004b). J. Cell. Biochem., 93, 358–373.

  • Chen JQ and Yager JD . (2004). Ann. NY Acad. Sci., 1028, 258–272.

  • Delsite R, Kachhap S, Anbazhagan R, Gabrielson E and Singh KK . (2002). Mol. Cancer, 1, 6.

  • Droge W . (2002). Physiol. Rev., 82, 47–95.

  • DuMond Jr JW, Singh KP and Roy D . (2001a). Int. J. Oncol., 18, 623–628.

  • DuMond Jr JW, Singh KP and Roy D . (2001b). Oncol. Rep., 8, 899–902.

  • Felty Q and Roy D . (2005a). J. Carcinogen., 4, 1.

  • Felty Q and Roy D . (2005b). Med. Hypotheses, 64, 133–141.

  • Formby B and Wiley TS . (1999). Mol. Cell. Biochem., 202, 53–61.

  • Foster JS, Henley DC, Ahamed S and Wimalasena J . (2001). Trends Endocrinol. Metab., 12, 320–327.

  • Galli S, Labato MI, Bal de Kier JE, Carreras MC and Poderoso JJ . (2003). Cancer Res., 63, 6370–6377.

  • Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E and McTiernan A . (2003). Cancer Res., 63, 6096–6101.

  • Herber B, Truss M, Beato M and Muller R . (1994a). Oncogene, 9, 1295–1304.

  • Herber B, Truss M, Beato M and Muller R . (1994b). Oncogene, 9, 1295–1304.

  • Honore S, Kovacic H, Pichard V, Briand C and Rognoni JB . (2003). Exp. Cell Res., 285, 59–71.

  • IARC working group (1999). Monographs on the Evaluation of Hormonal Contraception and Postmenopausal Hormonal Therapy [72], pp 399–530 (Ref Type: Serial (Book, Monograph)).

  • Janssen YM, Matalon S and Mossman BT . (1997). Am. J. Physiol., 273, L789–L796.

  • Kim MR, Chang HS, Kim BH, Kim S, Baek SH, Kim JH, Lee SR and Kim JR . (2003). Biochem. Biophys. Res. Commun., 304, 119–124.

  • King MP and Attardi G . (1996). Methods Enzymol., 264, 304–313.

  • Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mossner J and Engeland K . (2000). Nucleic Acids Res., 28, 4410–4418.

  • Liehr JG and Roy D . (1990). Free Radic. Biol. Med., 8, 415–423.

  • Liu Y, Fiskum G and Schubert D . (2002). J. Neurochem., 80, 780–787.

  • Maddaiah VT, Sharma RK, Balachandar V, Rezvani I, Collipp PJ and Chen SY . (1973). J. Biol. Chem., 248, 4263–4268.

  • Maruyama T, Sachi Y, Furuke K, Kitaoka Y, Kanzaki H, Yoshimura Y and Yodoi J . (1999). Endocrinology, 140, 365–372.

  • Menon SG, Sarsour EH, Spitz DR, Higashikubo R, Sturm M, Zhang H and Goswami PC . (2003). Cancer Res., 63, 2109–2117.

  • National Toxicology Program (2002). Federal Report on Carcinogens [67], pp 77283–77285 (Federal Register. Ref Type: Serial (Book,Monograph)).

  • Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP and Darley-Usmar VM . (2000). Antimicrob. Agents Chemother., 44, 496–503.

  • Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL and Leitman DC . (2004). Cancer Res., 64, 423–428.

  • Planas-Silva MD, Donaher JL and Weinberg RA . (1999). Cancer Res., 59, 4788–4792.

  • Ramachandran C, Melnick SJ, Escalon E, Jhabvala P, Khatib Z, Alamo A and Smith S . (2000). Anticancer Res., 20, 3759–3765.

  • Roy D and Cai Q . (2002). Recent Res. Dev. Steroid Biochem. Mol. Biol., 3, 1–32.

  • Roy D and Liehr JG . (1988). J. Biol. Chem., 263, 3646–3651.

  • Roy D and Singh KP . (2004). Curr. Genom., 5, 245–257.

  • Sabbah M, Courilleau D, Mester J and Redeuilh G . (1999). Proc. Natl. Acad. Sci. USA, 96, 11217–11222.

  • Sauer H, Wartenberg M and Hescheler J . (2001). Cell. Physiol. Biochem., 11, 173–186.

  • Shigenaga MK, Hagen TM and Ames BN . (1994). Proc. Natl. Acad. Sci. USA, 91, 10771–10778.

  • Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ and Weinberg RA . (1995). Cell, 82, 621–630.

  • Simon AR, Rai U, Fanburg BL and Cochran BH . (1998). Am. J. Physiol., 275, C1640–C1652.

  • Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR . (1990). J. Natl. Cancer Inst., 82, 1107–1112.

  • Szewczyk A and Wojtczak L . (2002). Pharmacol. Rev., 54, 101–127.

  • Turrens JF, Alexandre A and Lehninger AL . (1985). Arch. Biochem. Biophys., 237, 408–414.

  • Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T and Motokura T . (1997). Blood, 89, 965–974.

  • van den BC, van Kernebeek G, de Leij L and Kroon AM . (1986). Cancer Lett., 32, 41–51.

  • Wang TT and Phang JM . (1995). Cancer Res., 55, 2487–2489.

  • Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA and Kyritsis AP . (1997). Cancer Res., 57, 1673–1677.

  • Williams AJ, Murrell M, Brammah S, Minchenko J and Christodoulou J . (1999). Hum. Mol. Genet., 8, 1691–1697.

Download references

Acknowledgements

We highly appreciate the technical assistance of Marion Spell. This work was partly supported by the NIEHS Grant ES10851 to DR, and financial support to QF through NCI Cancer Prevention and Control Training Grant (CA 4788).

Author information

Authors and Affiliations

  1. Department of Environmental Health Sciences, University of Alabama at Birmingham, Birmingham, AL, USA

    Quentin Felty, Kamaleshwar P Singh & Deodutta Roy

  2. Robert Stempel School of Public Health, Florida International University, 11200 SW 8th Street, VH 231, Miami, 33199, FL, USA

    Deodutta Roy

Authors
  1. Quentin Felty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamaleshwar P Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deodutta Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deodutta Roy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Felty, Q., Singh, K. & Roy, D. Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 24, 4883–4893 (2005). https://doi.org/10.1038/sj.onc.1208667

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208667

Keywords

This article is cited by

Search

Advanced search

Quick links